A series of novel pyrazolyl alcohols (5a-h), pyrazolyl azides (6a-h), and pyrazolyltriazoles (8a-h, 10a-p and 12a-l) were prepared and evaluated for their bioactivity (anti-bacterial and anti-inflammatory) profile. The compound 5c displayed the potent anti-bacterial activity against Micrococcus luteus (MIC 3.9 and MBC 7.81 µg/mL). In vitro anti-inflammatory activity data denoted that compound 8b is effective among the tested compounds against IL-6 (IC₅₀ 6.23 μM). Docking analysis of compounds 5f, 8a-b, 8e-f and 8h displayed high binding energies for the compounds 8a-b and 8h towards TNF-α dimer (2AZ5 protein) and IL-6 (1ALU protein). In vivo anti-inflammatory activity of compounds 8b and 8h with respect to LPS induced mice model indicated that compound 8h showed significant reduction in TNF-α.

制备了一系列新型的吡唑基醇（5a-h），吡唑基叠氮化物（6a-h）和吡唑基三唑（8a-h，10a-p和12a-1），并对其生物活性进行了评估（抗菌和消炎） ） 轮廓。化合物5c对黄褐微球菌（MIC 3.9和MBC 7.81 µg / mL）表现出有效的抗菌活性。体外抗炎活性数据表明，化合物8b在被测化合物中对IL-6（IC ₅₀ 6.23μM）有效。化合物5f，8a-b，8e的对接分析- ˚F和8H显示高结合能为化合物8A-B和8H朝TNF-α二聚体（2AZ5蛋白）和IL-6（1ALU蛋白）。相对于LPS诱导的小鼠模型，化合物8b和8h的体内抗炎活性表明化合物8h显示出TNF-α的显着降低。